Global Beta Lactam and Beta Lactamase Inhibitors Market 2025-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	200 Pages	TechNavio	December, 2024	INF19463144

Best Price Guarantee
Price	from $2,500
Length	200 Pages
Publisher	TechNavio
Published Date	December, 2024
SKU	INF19463144

Beta Lactam And Beta Lactamase Inhibitors Market 2025-2029

The beta lactam and beta lactamase inhibitors market is forecasted to grow by USD 8400.9 mn during 2024-2029, accelerating at a CAGR of 4.7% during the forecast period. The report on the beta lactam and beta lactamase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising focus on novel drug development, rising antimicrobial resistance, and high disease burden in developing countries.

Technavio's beta lactam and beta lactamase inhibitors market is segmented as below:

By Route Of Administration

Oral
Intravenous
Others

By Drug Class

Cephalosporins
Penicillins
Carbapenem
Monobactum
Combination

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the technological advancements in antibiotic discovery as one of the prime reasons driving the beta lactam and beta lactamase inhibitors market growth during the next few years. Also, increased emphasis on antibiotic stewardship and growing emphasis on hais will lead to sizable demand in the market.

The report on the beta lactam and beta lactamase inhibitors market covers the following areas:

Beta Lactam And Beta Lactamase Inhibitors Market sizing
Beta Lactam And Beta Lactamase Inhibitors Market forecast
Beta Lactam And Beta Lactamase Inhibitors Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading beta lactam and beta lactamase inhibitors market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi SA, Spero Therapeutics Inc., Taj Pharmaceutical Ltd., and Zeelab Laboratories Ltd.. Also, the beta lactam and beta lactamase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Market Segmentation by Drug Class; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029
3 Market Landscape: 3.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Market characteristics analysis; 3.3 Value chain analysis; Value chain analysis
4 Market Sizing: 4.1 Market definition; Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2024; 4.4 Market outlook: Forecast for 2024-2029; Chart on Global - Market size and forecast 2024-2029 ($ million); Data Table on Global - Market size and forecast 2024-2029 ($ million); Chart on Global Market: Year-over-year growth 2024-2029 (%); Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size: 5.1 Global Beta Lactam And Beta Lactamase Inhibitors Market 2019 - 2023; Historic Market Size - Data Table on Global Beta Lactam And Beta Lactamase Inhibitors Market 2019 - 2023 ($ million); 5.2 Route of Administration segment analysis 2019 - 2023; Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million); 5.3 Drug Class segment analysis 2019 - 2023; Historic Market Size - Drug Class Segment 2019 - 2023 ($ million); 5.4 Geography segment analysis 2019 - 2023; Historic Market Size - Geography Segment 2019 - 2023 ($ million); 5.5 Country segment analysis 2019 - 2023; Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis: 6.1 The impact of AI in Global Beta Lactam and Beta Lactamase Inhibitors Market
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2024 and 2029; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2024 and 2029; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2024 and 2029; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2024 and 2029; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2024 and 2029; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2024 and 2029; 7.7 Market condition; Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Route of Administration: 8.1 Market segments; Chart on Route of Administration - Market share 2024-2029 (%); Data Table on Route of Administration - Market share 2024-2029 (%); 8.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 8.3 Oral - Market size and forecast 2024-2029; Chart on Oral - Market size and forecast 2024-2029 ($ million); Data Table on Oral - Market size and forecast 2024-2029 ($ million); Chart on Oral - Year-over-year growth 2024-2029 (%); Data Table on Oral - Year-over-year growth 2024-2029 (%); 8.4 Intravenous - Market size and forecast 2024-2029; Chart on Intravenous - Market size and forecast 2024-2029 ($ million); Data Table on Intravenous - Market size and forecast 2024-2029 ($ million); Chart on Intravenous - Year-over-year growth 2024-2029 (%); Data Table on Intravenous - Year-over-year growth 2024-2029 (%); 8.5 Others - Market size and forecast 2024-2029; Chart on Others - Market size and forecast 2024-2029 ($ million); Data Table on Others - Market size and forecast 2024-2029 ($ million); Chart on Others - Year-over-year growth 2024-2029 (%); Data Table on Others - Year-over-year growth 2024-2029 (%); 8.6 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
9 Market Segmentation by Drug Class: 9.1 Market segments; Chart on Drug Class - Market share 2024-2029 (%); Data Table on Drug Class - Market share 2024-2029 (%); 9.2 Comparison by Drug Class; Chart on Comparison by Drug Class; Data Table on Comparison by Drug Class; 9.3 Cephalosporins - Market size and forecast 2024-2029; Chart on Cephalosporins - Market size and forecast 2024-2029 ($ million); Data Table on Cephalosporins - Market size and forecast 2024-2029 ($ million); Chart on Cephalosporins - Year-over-year growth 2024-2029 (%); Data Table on Cephalosporins - Year-over-year growth 2024-2029 (%); 9.4 Penicillins - Market size and forecast 2024-2029; Chart on Penicillins - Market size and forecast 2024-2029 ($ million); Data Table on Penicillins - Market size and forecast 2024-2029 ($ million); Chart on Penicillins - Year-over-year growth 2024-2029 (%); Data Table on Penicillins - Year-over-year growth 2024-2029 (%); 9.5 Carbapenem - Market size and forecast 2024-2029; Chart on Carbapenem - Market size and forecast 2024-2029 ($ million); Data Table on Carbapenem - Market size and forecast 2024-2029 ($ million); Chart on Carbapenem - Year-over-year growth 2024-2029 (%); Data Table on Carbapenem - Year-over-year growth 2024-2029 (%); 9.6 Monobactum - Market size and forecast 2024-2029; Chart on Monobactum - Market size and forecast 2024-2029 ($ million); Data Table on Monobactum - Market size and forecast 2024-2029 ($ million); Chart on Monobactum - Year-over-year growth 2024-2029 (%); Data Table on Monobactum - Year-over-year growth 2024-2029 (%); 9.7 Combination - Market size and forecast 2024-2029; Chart on Combination - Market size and forecast 2024-2029 ($ million); Data Table on Combination - Market size and forecast 2024-2029 ($ million); Chart on Combination - Year-over-year growth 2024-2029 (%); Data Table on Combination - Year-over-year growth 2024-2029 (%); 9.8 Market opportunity by Drug Class; Market opportunity by Drug Class ($ million); Data Table on Market opportunity by Drug Class ($ million)
10 Customer Landscape: 10.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape: 11.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2024-2029 (%); Data Table on Market share By Geographical Landscape 2024-2029 (%); 11.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 11.3 North America - Market size and forecast 2024-2029; Chart on North America - Market size and forecast 2024-2029 ($ million); Data Table on North America - Market size and forecast 2024-2029 ($ million); Chart on North America - Year-over-year growth 2024-2029 (%); Data Table on North America - Year-over-year growth 2024-2029 (%); 11.4 Europe - Market size and forecast 2024-2029; Chart on Europe - Market size and forecast 2024-2029 ($ million); Data Table on Europe - Market size and forecast 2024-2029 ($ million); Chart on Europe - Year-over-year growth 2024-2029 (%); Data Table on Europe - Year-over-year growth 2024-2029 (%); 11.5 Asia - Market size and forecast 2024-2029; Chart on Asia - Market size and forecast 2024-2029 ($ million); Data Table on Asia - Market size and forecast 2024-2029 ($ million); Chart on Asia - Year-over-year growth 2024-2029 (%); Data Table on Asia - Year-over-year growth 2024-2029 (%); 11.6 Rest of World (ROW) - Market size and forecast 2024-2029; Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); 11.7 US - Market size and forecast 2024-2029; Chart on US - Market size and forecast 2024-2029 ($ million); Data Table on US - Market size and forecast 2024-2029 ($ million); Chart on US - Year-over-year growth 2024-2029 (%); Data Table on US - Year-over-year growth 2024-2029 (%); 11.8 China - Market size and forecast 2024-2029; Chart on China - Market size and forecast 2024-2029 ($ million); Data Table on China - Market size and forecast 2024-2029 ($ million); Chart on China - Year-over-year growth 2024-2029 (%); Data Table on China - Year-over-year growth 2024-2029 (%); 11.9 Germany - Market size and forecast 2024-2029; Chart on Germany - Market size and forecast 2024-2029 ($ million); Data Table on Germany - Market size and forecast 2024-2029 ($ million); Chart on Germany - Year-over-year growth 2024-2029 (%); Data Table on Germany - Year-over-year growth 2024-2029 (%); 11.10 India - Market size and forecast 2024-2029; Chart on India - Market size and forecast 2024-2029 ($ million); Data Table on India - Market size and forecast 2024-2029 ($ million); Chart on India - Year-over-year growth 2024-2029 (%); Data Table on India - Year-over-year growth 2024-2029 (%); 11.11 Japan - Market size and forecast 2024-2029; Chart on Japan - Market size and forecast 2024-2029 ($ million); Data Table on Japan - Market size and forecast 2024-2029 ($ million); Chart on Japan - Year-over-year growth 2024-2029 (%); Data Table on Japan - Year-over-year growth 2024-2029 (%); 11.12 UK - Market size and forecast 2024-2029; Chart on UK - Market size and forecast 2024-2029 ($ million); Data Table on UK - Market size and forecast 2024-2029 ($ million); Chart on UK - Year-over-year growth 2024-2029 (%); Data Table on UK - Year-over-year growth 2024-2029 (%); 11.13 Canada - Market size and forecast 2024-2029; Chart on Canada - Market size and forecast 2024-2029 ($ million); Data Table on Canada - Market size and forecast 2024-2029 ($ million); Chart on Canada - Year-over-year growth 2024-2029 (%); Data Table on Canada - Year-over-year growth 2024-2029 (%); 11.14 South Korea - Market size and forecast 2024-2029; Chart on South Korea - Market size and forecast 2024-2029 ($ million); Data Table on South Korea - Market size and forecast 2024-2029 ($ million); Chart on South Korea - Year-over-year growth 2024-2029 (%); Data Table on South Korea - Year-over-year growth 2024-2029 (%); 11.15 France - Market size and forecast 2024-2029; Chart on France - Market size and forecast 2024-2029 ($ million); Data Table on France - Market size and forecast 2024-2029 ($ million); Chart on France - Year-over-year growth 2024-2029 (%); Data Table on France - Year-over-year growth 2024-2029 (%); 11.16 Italy - Market size and forecast 2024-2029; Chart on Italy - Market size and forecast 2024-2029 ($ million); Data Table on Italy - Market size and forecast 2024-2029 ($ million); Chart on Italy - Year-over-year growth 2024-2029 (%); Data Table on Italy - Year-over-year growth 2024-2029 (%); 11.17 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
12 Drivers, Challenges, and Opportunity/Restraints: 12.1 Market drivers; 12.2 Market challenges; 12.3 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029; 12.4 Market opportunities/restraints
13 Competitive Landscape: 13.1 Overview; 13.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 13.3 Landscape disruption; Overview on factors of disruption; 13.4 Industry risks; Impact of key risks on business
14 Competitive Analysis: 14.1 Companies profiled; Companies covered; 14.2 Company ranking index; Company ranking index; 14.3 Market positioning of companies; Matrix on companies position and classification; 14.4 Abbott Laboratories; Abbott Laboratories - Overview; Abbott Laboratories - Business segments; Abbott Laboratories - Key news; Abbott Laboratories - Key offerings; Abbott Laboratories - Segment focus; SWOT; 14.5 AbbVie Inc.; AbbVie Inc. - Overview; AbbVie Inc. - Product / Service; AbbVie Inc. - Key news; AbbVie Inc. - Key offerings; SWOT; 14.6 Alkem Laboratories Ltd.; Alkem Laboratories Ltd. - Overview; Alkem Laboratories Ltd. - Business segments; Alkem Laboratories Ltd. - Key offerings; Alkem Laboratories Ltd. - Segment focus; SWOT; 14.7 Astellas Pharma Inc.; Astellas Pharma Inc. - Overview; Astellas Pharma Inc. - Product / Service; Astellas Pharma Inc. - Key offerings; SWOT; 14.8 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; SWOT; 14.9 F. Hoffmann La Roche Ltd.; F. Hoffmann La Roche Ltd. - Overview; F. Hoffmann La Roche Ltd. - Business segments; F. Hoffmann La Roche Ltd. - Key news; F. Hoffmann La Roche Ltd. - Key offerings; F. Hoffmann La Roche Ltd. - Segment focus; SWOT; 14.10 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; SWOT; 14.11 Lupin Ltd.; Lupin Ltd. - Overview; Lupin Ltd. - Business segments; Lupin Ltd. - Key news; Lupin Ltd. - Key offerings; Lupin Ltd. - Segment focus; SWOT; 14.12 Meiji Holdings Co. Ltd.; Meiji Holdings Co. Ltd. - Overview; Meiji Holdings Co. Ltd. - Business segments; Meiji Holdings Co. Ltd. - Key news; Meiji Holdings Co. Ltd. - Key offerings; Meiji Holdings Co. Ltd. - Segment focus; SWOT; 14.13 Merck KGaA; Merck KGaA - Overview; Merck KGaA - Business segments; Merck KGaA - Key news; Merck KGaA - Key offerings; Merck KGaA - Segment focus; SWOT; 14.14 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; SWOT; 14.15 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 14.16 Sandoz Group AG; Sandoz Group AG - Overview; Sandoz Group AG - Product / Service; Sandoz Group AG - Key offerings; SWOT; 14.17 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 14.18 Spero Therapeutics Inc.; Spero Therapeutics Inc. - Overview; Spero Therapeutics Inc. - Product / Service; Spero Therapeutics Inc. - Key offerings; SWOT
15 Appendix: 15.1 Scope of the report; 15.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 15.3 Currency conversion rates for US$; Currency conversion rates for US$; 15.4 Research methodology; Research methodology; 15.5 Data procurement; Information sources; 15.6 Data validation; Data validation; 15.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 15.8 Data synthesis; Data synthesis; 15.9 360 degree market analysis; 360 degree market analysis; 15.10 List of abbreviations; List of abbreviations; o Strong financial performance
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits11: Overview on criticality of inputs and factors of differentiation; Exhibits12: Overview on factors of disruption; Exhibits13: Impact of drivers and challenges in 2024 and 2029; Exhibits14: Parent Market; Exhibits15: Data Table on - Parent Market; Exhibits16: Market characteristics analysis; Exhibits17: Value chain analysis; Exhibits18: Offerings of companies included in the market definition; Exhibits19: Market segments; Exhibits20: Chart on Global - Market size and forecast 2024-2029 ($ million); Exhibits21: Data Table on Global - Market size and forecast 2024-2029 ($ million); Exhibits22: Chart on Global Market: Year-over-year growth 2024-2029 (%); Exhibits23: Data Table on Global Market: Year-over-year growth 2024-2029 (%); Exhibits24: Historic Market Size - Data Table on Global Beta Lactam And Beta Lactamase Inhibitors Market 2019 - 2023 ($ million); Exhibits25: Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million); Exhibits26: Historic Market Size - Drug Class Segment 2019 - 2023 ($ million); Exhibits27: Historic Market Size - Geography Segment 2019 - 2023 ($ million); Exhibits28: Historic Market Size - Country Segment 2019 - 2023 ($ million); Exhibits29: Five forces analysis - Comparison between 2024 and 2029; Exhibits30: Bargaining power of buyers - Impact of key factors 2024 and 2029; Exhibits31: Bargaining power of suppliers - Impact of key factors in 2024 and 2029; Exhibits32: Threat of new entrants - Impact of key factors in 2024 and 2029; Exhibits33: Threat of substitutes - Impact of key factors in 2024 and 2029; Exhibits34: Threat of rivalry - Impact of key factors in 2024 and 2029; Exhibits35: Chart on Market condition - Five forces 2024 and 2029; Exhibits36: Chart on Route of Administration - Market share 2024-2029 (%); Exhibits37: Data Table on Route of Administration - Market share 2024-2029 (%); Exhibits38: Chart on Comparison by Route of Administration; Exhibits39: Data Table on Comparison by Route of Administration; Exhibits40: Chart on Oral - Market size and forecast 2024-2029 ($ million); Exhibits41: Data Table on Oral - Market size and forecast 2024-2029 ($ million); Exhibits42: Chart on Oral - Year-over-year growth 2024-2029 (%); Exhibits43: Data Table on Oral - Year-over-year growth 2024-2029 (%); Exhibits44: Chart on Intravenous - Market size and forecast 2024-2029 ($ million); Exhibits45: Data Table on Intravenous - Market size and forecast 2024-2029 ($ million); Exhibits46: Chart on Intravenous - Year-over-year growth 2024-2029 (%); Exhibits47: Data Table on Intravenous - Year-over-year growth 2024-2029 (%); Exhibits48: Chart on Others - Market size and forecast 2024-2029 ($ million); Exhibits49: Data Table on Others - Market size and forecast 2024-2029 ($ million); Exhibits50: Chart on Others - Year-over-year growth 2024-2029 (%); Exhibits51: Data Table on Others - Year-over-year growth 2024-2029 (%); Exhibits52: Market opportunity by Route of Administration ($ million); Exhibits53: Data Table on Market opportunity by Route of Administration ($ million); Exhibits54: Chart on Drug Class - Market share 2024-2029 (%); Exhibits55: Data Table on Drug Class - Market share 2024-2029 (%); Exhibits56: Chart on Comparison by Drug Class; Exhibits57: Data Table on Comparison by Drug Class; Exhibits58: Chart on Cephalosporins - Market size and forecast 2024-2029 ($ million); Exhibits59: Data Table on Cephalosporins - Market size and forecast 2024-2029 ($ million); Exhibits60: Chart on Cephalosporins - Year-over-year growth 2024-2029 (%); Exhibits61: Data Table on Cephalosporins - Year-over-year growth 2024-2029 (%); Exhibits62: Chart on Penicillins - Market size and forecast 2024-2029 ($ million); Exhibits63: Data Table on Penicillins - Market size and forecast 2024-2029 ($ million); Exhibits64: Chart on Penicillins - Year-over-year growth 2024-2029 (%); Exhibits65: Data Table on Penicillins - Year-over-year growth 2024-2029 (%); Exhibits66: Chart on Carbapenem - Market size and forecast 2024-2029 ($ million); Exhibits67: Data Table on Carbapenem - Market size and forecast 2024-2029 ($ million); Exhibits68: Chart on Carbapenem - Year-over-year growth 2024-2029 (%); Exhibits69: Data Table on Carbapenem - Year-over-year growth 2024-2029 (%); Exhibits70: Chart on Monobactum - Market size and forecast 2024-2029 ($ million); Exhibits71: Data Table on Monobactum - Market size and forecast 2024-2029 ($ million); Exhibits72: Chart on Monobactum - Year-over-year growth 2024-2029 (%); Exhibits73: Data Table on Monobactum - Year-over-year growth 2024-2029 (%); Exhibits74: Chart on Combination - Market size and forecast 2024-2029 ($ million); Exhibits75: Data Table on Combination - Market size and forecast 2024-2029 ($ million); Exhibits76: Chart on Combination - Year-over-year growth 2024-2029 (%); Exhibits77: Data Table on Combination - Year-over-year growth 2024-2029 (%); Exhibits78: Market opportunity by Drug Class ($ million); Exhibits79: Data Table on Market opportunity by Drug Class ($ million); Exhibits80: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits81: Chart on Market share By Geographical Landscape 2024-2029 (%); Exhibits82: Data Table on Market share By Geographical Landscape 2024-2029 (%); Exhibits83: Chart on Geographic comparison; Exhibits84: Data Table on Geographic comparison; Exhibits85: Chart on North America - Market size and forecast 2024-2029 ($ million); Exhibits86: Data Table on North America - Market size and forecast 2024-2029 ($ million); Exhibits87: Chart on North America - Year-over-year growth 2024-2029 (%); Exhibits88: Data Table on North America - Year-over-year growth 2024-2029 (%); Exhibits89: Chart on Europe - Market size and forecast 2024-2029 ($ million); Exhibits90: Data Table on Europe - Market size and forecast 2024-2029 ($ million); Exhibits91: Chart on Europe - Year-over-year growth 2024-2029 (%); Exhibits92: Data Table on Europe - Year-over-year growth 2024-2029 (%); Exhibits93: Chart on Asia - Market size and forecast 2024-2029 ($ million); Exhibits94: Data Table on Asia - Market size and forecast 2024-2029 ($ million); Exhibits95: Chart on Asia - Year-over-year growth 2024-2029 (%); Exhibits96: Data Table on Asia - Year-over-year growth 2024-2029 (%); Exhibits97: Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Exhibits98: Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Exhibits99: Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); Exhibits100: Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); Exhibits101: Chart on US - Market size and forecast 2024-2029 ($ million); Exhibits102: Data Table on US - Market size and forecast 2024-2029 ($ million); Exhibits103: Chart on US - Year-over-year growth 2024-2029 (%); Exhibits104: Data Table on US - Year-over-year growth 2024-2029 (%); Exhibits105: Chart on China - Market size and forecast 2024-2029 ($ million); Exhibits106: Data Table on China - Market size and forecast 2024-2029 ($ million); Exhibits107: Chart on China - Year-over-year growth 2024-2029 (%); Exhibits108: Data Table on China - Year-over-year growth 2024-2029 (%); Exhibits109: Chart on Germany - Market size and forecast 2024-2029 ($ million); Exhibits110: Data Table on Germany - Market size and forecast 2024-2029 ($ million); Exhibits111: Chart on Germany - Year-over-year growth 2024-2029 (%); Exhibits112: Data Table on Germany - Year-over-year growth 2024-2029 (%); Exhibits113: Chart on India - Market size and forecast 2024-2029 ($ million); Exhibits114: Data Table on India - Market size and forecast 2024-2029 ($ million); Exhibits115: Chart on India - Year-over-year growth 2024-2029 (%); Exhibits116: Data Table on India - Year-over-year growth 2024-2029 (%); Exhibits117: Chart on Japan - Market size and forecast 2024-2029 ($ million); Exhibits118: Data Table on Japan - Market size and forecast 2024-2029 ($ million); Exhibits119: Chart on Japan - Year-over-year growth 2024-2029 (%); Exhibits120: Data Table on Japan - Year-over-year growth 2024-2029 (%); Exhibits121: Chart on UK - Market size and forecast 2024-2029 ($ million); Exhibits122: Data Table on UK - Market size and forecast 2024-2029 ($ million); Exhibits123: Chart on UK - Year-over-year growth 2024-2029 (%); Exhibits124: Data Table on UK - Year-over-year growth 2024-2029 (%); Exhibits125: Chart on Canada - Market size and forecast 2024-2029 ($ million); Exhibits126: Data Table on Canada - Market size and forecast 2024-2029 ($ million); Exhibits127: Chart on Canada - Year-over-year growth 2024-2029 (%); Exhibits128: Data Table on Canada - Year-over-year growth 2024-2029 (%); Exhibits129: Chart on South Korea - Market size and forecast 2024-2029 ($ million); Exhibits130: Data Table on South Korea - Market size and forecast 2024-2029 ($ million); Exhibits131: Chart on South Korea - Year-over-year growth 2024-2029 (%); Exhibits132: Data Table on South Korea - Year-over-year growth 2024-2029 (%); Exhibits133: Chart on France - Market size and forecast 2024-2029 ($ million); Exhibits134: Data Table on France - Market size and forecast 2024-2029 ($ million); Exhibits135: Chart on France - Year-over-year growth 2024-2029 (%); Exhibits136: Data Table on France - Year-over-year growth 2024-2029 (%); Exhibits137: Chart on Italy - Market size and forecast 2024-2029 ($ million); Exhibits138: Data Table on Italy - Market size and forecast 2024-2029 ($ million); Exhibits139: Chart on Italy - Year-over-year growth 2024-2029 (%); Exhibits140: Data Table on Italy - Year-over-year growth 2024-2029 (%); Exhibits141: Market opportunity By Geographical Landscape ($ million); Exhibits142: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits143: Impact of drivers and challenges in 2024 and 2029; Exhibits144: Overview on criticality of inputs and factors of differentiation; Exhibits145: Overview on factors of disruption; Exhibits146: Impact of key risks on business; Exhibits147: Companies covered; Exhibits148: Company ranking index; Exhibits149: Matrix on companies position and classification; Exhibits150: Abbott Laboratories - Overview; Exhibits151: Abbott Laboratories - Business segments; Exhibits152: Abbott Laboratories - Key news; Exhibits153: Abbott Laboratories - Key offerings; Exhibits154: Abbott Laboratories - Segment focus; Exhibits155: SWOT; Exhibits156: AbbVie Inc. - Overview; Exhibits157: AbbVie Inc. - Product / Service; Exhibits158: AbbVie Inc. - Key news; Exhibits159: AbbVie Inc. - Key offerings; Exhibits160: SWOT; Exhibits161: Alkem Laboratories Ltd. - Overview; Exhibits162: Alkem Laboratories Ltd. - Business segments; Exhibits163: Alkem Laboratories Ltd. - Key offerings; Exhibits164: Alkem Laboratories Ltd. - Segment focus; Exhibits165: SWOT; Exhibits166: Astellas Pharma Inc. - Overview; Exhibits167: Astellas Pharma Inc. - Product / Service; Exhibits168: Astellas Pharma Inc. - Key offerings; Exhibits169: SWOT; Exhibits170: Cipla Inc. - Overview; Exhibits171: Cipla Inc. - Business segments; Exhibits172: Cipla Inc. - Key news; Exhibits173: Cipla Inc. - Key offerings; Exhibits174: Cipla Inc. - Segment focus; Exhibits175: SWOT; Exhibits176: F. Hoffmann La Roche Ltd. - Overview; Exhibits177: F. Hoffmann La Roche Ltd. - Business segments; Exhibits178: F. Hoffmann La Roche Ltd. - Key news; Exhibits179: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits180: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits181: SWOT; Exhibits182: GlaxoSmithKline Plc - Overview; Exhibits183: GlaxoSmithKline Plc - Business segments; Exhibits184: GlaxoSmithKline Plc - Key news; Exhibits185: GlaxoSmithKline Plc - Key offerings; Exhibits186: GlaxoSmithKline Plc - Segment focus; Exhibits187: SWOT; Exhibits188: Lupin Ltd. - Overview; Exhibits189: Lupin Ltd. - Business segments; Exhibits190: Lupin Ltd. - Key news; Exhibits191: Lupin Ltd. - Key offerings; Exhibits192: Lupin Ltd. - Segment focus; Exhibits193: SWOT; Exhibits194: Meiji Holdings Co. Ltd. - Overview; Exhibits195: Meiji Holdings Co. Ltd. - Business segments; Exhibits196: Meiji Holdings Co. Ltd. - Key news; Exhibits197: Meiji Holdings Co. Ltd. - Key offerings; Exhibits198: Meiji Holdings Co. Ltd. - Segment focus; Exhibits199: SWOT; Exhibits200: Merck KGaA - Overview; Exhibits201: Merck KGaA - Business segments; Exhibits202: Merck KGaA - Key news; Exhibits203: Merck KGaA - Key offerings